stockportfolio.pro
ARGX vs IDXX: Which Stock Is the Better Buy?
argenx SE and IDEXX Laboratories, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ARGX vs IDXX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| argenx SE (ARGX) | IDEXX Laboratories, Inc. (IDXX) | |
|---|---|---|
| Market cap | $55.7B | $44.0B |
| Revenue (latest FY) | $4.15B | $4.30B |
| Net income (latest FY) | $1.29B | $1.06B |
| Revenue growth (5y CAGR) | 116.2% | 9.7% |
| Net margin | 31.1% | 24.6% |
| Return on equity | 17.6% | 66.0% |
| P/E ratio | 39.6 | 41.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 10 |
| Positive free cash flow | Yes | Yes |
See the full ARGX vs IDXX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARGX's full financials → Open IDXX's full financials →More comparisons
Frequently asked questions
Which is bigger, ARGX or IDXX?
argenx SE is larger by market capitalization — $55.7B versus $44.0B.
Which grows faster, ARGX or IDXX?
Over the last five fiscal years, argenx SE grew revenue faster — 116.2%/yr versus 9.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.